RespireRx Pharmaceuticals Inc. (RSPI)
USD 0.0
(15.0%)
USD 0.0
(15.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 1.57 Million USD | -38.29% |
| 2021 | 2.55 Million USD | -22.8% |
| 2020 | 3.31 Million USD | 90.91% |
| 2019 | 1.73 Million USD | -20.22% |
| 2018 | 2.17 Million USD | -48.76% |
| 2017 | 4.24 Million USD | -49.86% |
| 2016 | 8.47 Million USD | 59.05% |
| 2015 | 5.32 Million USD | 20.64% |
| 2014 | 4.41 Million USD | 287.34% |
| 2013 | 1.13 Million USD | -58.9% |
| 2012 | 2.77 Million USD | -48.42% |
| 2011 | 5.37 Million USD | -35.16% |
| 2010 | 8.29 Million USD | -0.52% |
| 2009 | 8.33 Million USD | -44.58% |
| 2008 | 15.03 Million USD | 10.2% |
| 2007 | 13.64 Million USD | -23.67% |
| 2006 | 17.87 Million USD | 21.31% |
| 2005 | 14.73 Million USD | -99.85% |
| 2004 | 9.51 Billion USD | 148045.28% |
| 2003 | 6.42 Million USD | -14.24% |
| 2002 | 7.48 Million USD | 9.45% |
| 2001 | 6.84 Million USD | 16.26% |
| 2000 | 5.88 Million USD | 23.06% |
| 1999 | 4.78 Million USD | -14.49% |
| 1998 | 5.59 Million USD | 9.95% |
| 1997 | 5.08 Million USD | 17.69% |
| 1996 | 4.32 Million USD | 39.4% |
| 1995 | 3.1 Million USD | 40.91% |
| 1994 | 2.2 Million USD | 37.5% |
| 1993 | 1.6 Million USD | 14.29% |
| 1992 | 1.4 Million USD | 40.0% |
| 1991 | 1 Million USD | 900.0% |
| 1990 | 100 Thousand USD | -92.31% |
| 1989 | 1.3 Million USD | 282.35% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 390.37 Thousand USD | 76.67% |
| 2023 Q3 | 332.5 Thousand USD | -28.62% |
| 2023 Q2 | 465.85 Thousand USD | 19.34% |
| 2022 Q3 | 388.96 Thousand USD | 10.35% |
| 2022 Q2 | 352.47 Thousand USD | -42.87% |
| 2022 FY | 1.57 Million USD | -38.29% |
| 2022 Q1 | 616.95 Thousand USD | 20.1% |
| 2022 Q4 | 220.96 Thousand USD | -43.19% |
| 2021 Q3 | 581.3 Thousand USD | -12.45% |
| 2021 Q4 | 513.68 Thousand USD | -11.63% |
| 2021 FY | 2.55 Million USD | -22.8% |
| 2021 Q1 | 800.14 Thousand USD | -7.57% |
| 2021 Q2 | 663.99 Thousand USD | -17.01% |
| 2020 Q2 | 616.91 Thousand USD | 18.51% |
| 2020 FY | 3.31 Million USD | 90.91% |
| 2020 Q3 | 1.31 Million USD | 112.67% |
| 2020 Q4 | 865.67 Thousand USD | -34.02% |
| 2020 Q1 | 520.57 Thousand USD | 25.8% |
| 2019 Q4 | 413.79 Thousand USD | -3.87% |
| 2019 Q1 | 473.86 Thousand USD | -18.29% |
| 2019 FY | 1.73 Million USD | -20.22% |
| 2019 Q2 | 418.39 Thousand USD | -11.71% |
| 2019 Q3 | 430.45 Thousand USD | 2.88% |
| 2018 Q4 | 579.92 Thousand USD | 15.16% |
| 2018 Q2 | 586.82 Thousand USD | 15.93% |
| 2018 FY | 2.17 Million USD | -48.76% |
| 2018 Q3 | 503.59 Thousand USD | -14.18% |
| 2018 Q1 | 506.17 Thousand USD | -26.0% |
| 2017 FY | 4.24 Million USD | -49.86% |
| 2017 Q2 | 1.54 Million USD | 9.07% |
| 2017 Q1 | 1.42 Million USD | -2.43% |
| 2017 Q3 | 593.14 Thousand USD | -61.72% |
| 2017 Q4 | 684.06 Thousand USD | 15.33% |
| 2016 FY | 8.47 Million USD | 59.05% |
| 2016 Q2 | 2.34 Million USD | -2.78% |
| 2016 Q3 | 2.24 Million USD | -4.26% |
| 2016 Q1 | 2.41 Million USD | 54.84% |
| 2016 Q4 | 1.45 Million USD | -35.27% |
| 2015 Q4 | 1.56 Million USD | -22.82% |
| 2015 Q2 | 1.07 Million USD | 98.33% |
| 2015 Q1 | 540.87 Thousand USD | -27.94% |
| 2015 FY | 5.32 Million USD | 20.64% |
| 2015 Q3 | 2.02 Million USD | 88.51% |
| 2014 FY | 4.41 Million USD | 287.34% |
| 2014 Q2 | 287.68 Thousand USD | -88.07% |
| 2014 Q1 | 2.41 Million USD | 3981.55% |
| 2014 Q4 | 750.57 Thousand USD | -22.2% |
| 2014 Q3 | 964.74 Thousand USD | 235.34% |
| 2013 Q3 | 58.34 Thousand USD | -67.44% |
| 2013 Q1 | 843.21 Thousand USD | 111.56% |
| 2013 FY | 1.13 Million USD | -58.9% |
| 2013 Q4 | 59.1 Thousand USD | 1.29% |
| 2013 Q2 | 179.22 Thousand USD | -78.75% |
| 2012 Q1 | 934.35 Thousand USD | -20.05% |
| 2012 Q2 | 1.02 Million USD | 9.17% |
| 2012 Q3 | 581.27 Thousand USD | -43.01% |
| 2012 FY | 2.77 Million USD | -48.42% |
| 2012 Q4 | 398.58 Thousand USD | -31.43% |
| 2011 Q2 | 1.44 Million USD | -8.54% |
| 2011 FY | 5.37 Million USD | -35.16% |
| 2011 Q4 | 1.16 Million USD | -0.48% |
| 2011 Q3 | 1.17 Million USD | -18.95% |
| 2011 Q1 | 1.58 Million USD | 25.03% |
| 2010 Q1 | 3.33 Million USD | 125.99% |
| 2010 Q2 | 1.96 Million USD | -40.89% |
| 2010 Q3 | 1.72 Million USD | -12.49% |
| 2010 FY | 8.29 Million USD | -0.52% |
| 2010 Q4 | 1.26 Million USD | -26.47% |
| 2009 FY | 8.33 Million USD | -44.58% |
| 2009 Q1 | 3.18 Million USD | 0.34% |
| 2009 Q2 | 1.94 Million USD | -38.79% |
| 2009 Q3 | 1.72 Million USD | -11.29% |
| 2009 Q4 | 1.47 Million USD | -14.72% |
| 2008 FY | 15.03 Million USD | 10.2% |
| 2008 Q4 | 3.17 Million USD | -1.8% |
| 2008 Q3 | 3.23 Million USD | -20.74% |
| 2008 Q2 | 4.07 Million USD | -10.6% |
| 2008 Q1 | 4.55 Million USD | 29.36% |
| 2007 Q3 | 3.12 Million USD | 5.08% |
| 2007 Q2 | 2.97 Million USD | -26.19% |
| 2007 Q1 | 4.02 Million USD | 2.96% |
| 2007 FY | 13.64 Million USD | -23.67% |
| 2007 Q4 | 3.52 Million USD | 12.86% |
| 2006 Q1 | 4.94 Million USD | 9.64% |
| 2006 Q4 | 3.91 Million USD | -7.0% |
| 2006 Q3 | 4.2 Million USD | -12.74% |
| 2006 FY | 17.87 Million USD | 21.31% |
| 2006 Q2 | 4.82 Million USD | -2.44% |
| 2005 FY | 14.73 Million USD | -99.85% |
| 2005 Q2 | 3.33 Million USD | -2.6% |
| 2005 Q1 | 3.42 Million USD | -99.96% |
| 2005 Q4 | 4.5 Million USD | 35.85% |
| 2005 Q3 | 3.31 Million USD | -0.56% |
| 2004 Q4 | 9.5 Billion USD | 344796.5% |
| 2004 Q3 | 2.75 Million USD | 4.73% |
| 2004 Q2 | 2.63 Million USD | 33.75% |
| 2004 Q1 | 1.96 Million USD | -36.48% |
| 2004 FY | 9.51 Billion USD | 148045.28% |
| 2003 FY | 6.42 Million USD | -14.24% |
| 2003 Q3 | 1.81 Million USD | 26.51% |
| 2003 Q2 | 1.43 Million USD | -5.62% |
| 2003 Q1 | 1.52 Million USD | -8.42% |
| 2003 Q4 | 3.09 Million USD | 70.59% |
| 2002 FY | 7.48 Million USD | 9.45% |
| 2002 Q4 | 1.66 Million USD | -7.97% |
| 2002 Q3 | 1.8 Million USD | 20.38% |
| 2002 Q2 | 1.49 Million USD | -25.18% |
| 2002 Q1 | 2 Million USD | -3.55% |
| 2001 Q1 | 1.6 Million USD | 21.23% |
| 2001 Q2 | 1.8 Million USD | 12.52% |
| 2001 Q3 | 1.9 Million USD | 5.72% |
| 2001 Q4 | 2.07 Million USD | 8.86% |
| 2001 FY | 6.84 Million USD | 16.26% |
| 2000 Q3 | 2.1 Million USD | 22.36% |
| 2000 FY | 5.88 Million USD | 23.06% |
| 2000 Q1 | 1.54 Million USD | 6.82% |
| 2000 Q2 | 1.72 Million USD | 11.49% |
| 2000 Q4 | 1.32 Million USD | -37.28% |
| 1999 Q2 | 1.16 Million USD | -21.62% |
| 1999 Q4 | 1.44 Million USD | 24.15% |
| 1999 Q3 | 1.16 Million USD | 0.52% |
| 1999 FY | 4.78 Million USD | -14.49% |
| 1999 Q1 | 1.48 Million USD | 64.44% |
| 1998 Q4 | 900 Thousand USD | -30.77% |
| 1998 Q1 | 1.7 Million USD | 21.43% |
| 1998 Q2 | 1.09 Million USD | -35.77% |
| 1998 Q3 | 1.3 Million USD | 19.07% |
| 1998 FY | 5.59 Million USD | 9.95% |
| 1997 Q4 | 1.4 Million USD | 7.69% |
| 1997 Q3 | 1.3 Million USD | 19.75% |
| 1997 Q2 | 1.08 Million USD | -16.49% |
| 1997 FY | 5.08 Million USD | 17.69% |
| 1997 Q1 | 1.3 Million USD | -7.14% |
| 1996 Q1 | 1.2 Million USD | 0.0% |
| 1996 Q4 | 1.4 Million USD | 16.67% |
| 1996 Q3 | 1.2 Million USD | 46.11% |
| 1996 Q2 | 821.3 Thousand USD | -31.56% |
| 1996 FY | 4.32 Million USD | 39.4% |
| 1995 FY | 3.1 Million USD | 40.91% |
| 1995 Q2 | 1.4 Million USD | 100.0% |
| 1995 Q3 | 400 Thousand USD | -71.43% |
| 1995 Q4 | 1.2 Million USD | 200.0% |
| 1995 Q1 | 700 Thousand USD | 16.67% |
| 1994 Q3 | 400 Thousand USD | -33.33% |
| 1994 FY | 2.2 Million USD | 37.5% |
| 1994 Q4 | 600 Thousand USD | 50.0% |
| 1994 Q2 | 600 Thousand USD | 0.0% |
| 1994 Q1 | 600 Thousand USD | 152.63% |
| 1993 FY | 1.6 Million USD | 14.29% |
| 1993 Q1 | 300 Thousand USD | 135.71% |
| 1993 Q2 | 600 Thousand USD | 100.0% |
| 1993 Q3 | -1.04 Million USD | -273.33% |
| 1993 Q4 | -1.14 Million USD | -9.62% |
| 1992 FY | 1.4 Million USD | 40.0% |
| 1992 Q1 | -530 Thousand USD | 43.01% |
| 1992 Q2 | -1.44 Million USD | -171.7% |
| 1992 Q3 | -940 Thousand USD | 34.72% |
| 1992 Q4 | -840 Thousand USD | 10.64% |
| 1991 FY | 1 Million USD | 900.0% |
| 1991 Q1 | -820 Thousand USD | -12.33% |
| 1991 Q4 | -930 Thousand USD | 0.0% |
| 1991 Q3 | -930 Thousand USD | -12.05% |
| 1991 Q2 | -830 Thousand USD | -1.22% |
| 1990 Q2 | -610 Thousand USD | 15.28% |
| 1990 FY | 100 Thousand USD | -92.31% |
| 1990 Q3 | -630 Thousand USD | -3.28% |
| 1990 Q4 | -730 Thousand USD | -15.87% |
| 1990 Q1 | -720 Thousand USD | -14.29% |
| 1989 Q4 | -630 Thousand USD | -1.61% |
| 1989 Q2 | -320 Thousand USD | 0.0% |
| 1989 Q3 | -620 Thousand USD | -93.75% |
| 1989 Q1 | - USD | 0.0% |
| 1989 FY | 1.3 Million USD | 282.35% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -18.266% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 68.676% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 94.656% |
| Nascent Biotech, Inc. | 2.22 Million USD | 29.173% |
| Rebus Holdings, Inc. | 664 Thousand USD | -137.855% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 95.761% |
| Qrons Inc. | 643.67 Thousand USD | -145.365% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -305.414% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 97.25% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -280.129% |
| Skye Bioscience, Inc. | 13.54 Million USD | 88.342% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.18% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 67.886% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -503.438% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.155% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 45.843% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -5.157% |
| Mesoblast Limited | 5.9 Million USD | 73.24% |
| Marizyme, Inc. | 19.23 Million USD | 91.791% |
| Genus plc | 147.7 Million USD | 98.931% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 82.01% |
| Pharming Group N.V. | 225.49 Million USD | 99.3% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 22.91% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -17.727% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 81.061% |
| ContraFect Corporation | 56.88 Million USD | 97.224% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 64.176% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -6.803% |
| IMV Inc. | 37.7 Million USD | 95.812% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 43.4% |
| MultiCell Technologies, Inc. | 567.42 USD | -278239.678% |
| ONE Bio Corp. | 6.44 Million USD | 75.491% |
| Accustem Sciences Inc. | 3.74 Million USD | 57.844% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.162% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -196.892% |
| Q BioMed Inc. | 3.43 Million USD | 54.043% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 93.61% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 39.892% |
| Biomind Labs Inc. | 994.18 Thousand USD | -58.86% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.41% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 10.247% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 76.491% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 15.287% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 6417.42% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 90.135% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 13.936% |
| GB Sciences, Inc. | 1.42 Million USD | -11.182% |
| Alpha Cognition Inc. | 9.7 Million USD | 83.727% |
| HST Global, Inc. | 140.9 Thousand USD | -1020.849% |
| CSL Limited | 3.44 Billion USD | 99.954% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -40.398% |
| Halberd Corporation | 74.84 Thousand USD | -2010.252% |
| Enzolytics Inc. | 2.17 Million USD | 27.536% |
| Agentix Corp. | 1.37 Million USD | -15.134% |
| Resverlogix Corp. | 12.71 Million USD | 87.576% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 56.738% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.897% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -51.279% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 34.329% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 53.616% |
| AVAX Technologies, Inc. | 7.31 Million USD | 78.395% |
| Zenith Capital Corp. | 8.94 Million USD | 82.34% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.809% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -8965.811% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 35.676% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -820.858% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 17.781% |
| Kadimastem Ltd | 2.41 Million USD | 34.47% |
| Helix BioMedix, Inc. | 1.97 Million USD | 19.912% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 85.467% |
| BioStem Technologies, Inc. | 22.97 Million USD | 93.126% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -770.24% |
| LadRx Corporation | 3.81 Million USD | 58.567% |
| Cell Source, Inc. | 4.32 Million USD | 63.486% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -71.017% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -71.017% |
| NovAccess Global Inc. | 2.46 Million USD | 35.975% |
| Affymax, Inc. | 39.38 Million USD | 95.99% |
| Itoco Inc. | 919.14 Thousand USD | -71.829% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 62.737% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -41.14% |
| Mobile Lads Corp. | 554.54 Thousand USD | -184.801% |
| CytoDyn Inc. | 18.05 Million USD | 91.254% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -6175.001% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -617.634% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -11.238% |
| SYBLEU INC | 160.87 Thousand USD | -881.722% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 13.046% |
| International Stem Cell Corporation | 5.27 Million USD | 70.037% |
| Bioxytran, Inc. | 3.82 Million USD | 58.657% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2900.18% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -7663.629% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 95.645% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 2.388% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -114.634% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 49.233% |
| Neutra Corp. | 243.82 Thousand USD | -547.752% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 90.953% |
| PureTech Health plc | 144.59 Million USD | 98.908% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 92.292% |
| IXICO plc | 4.7 Million USD | 66.447% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 82.047% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.659% |
| CSL Limited | 3.89 Billion USD | 99.959% |
| Cellectis S.A. | 97.32 Million USD | 98.377% |